Stock IMUX IMMUNIC, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Immunic, Inc.

Equities

IMUX

US4525EP1011

Real-time Estimate Cboe BZX
Other stock markets
 12:30:42 2024-06-05 pm EDT 		5-day change 1st Jan Change
1.25 USD +3.31% Intraday chart for Immunic, Inc. +1.22% -17.00%
May. 08 Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08 Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day
AQ
Immunic to Participate in Industry and Scientific Conferences in June
PR
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
AQ
Immunic chief medical officer discusses promising treatments to mark World IBD Day
AQ
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
AQ
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
AQ
Immunic : Q1 2024 News Release
PU
Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Immunic: Q1 Earnings Snapshot
AQ
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR
Immunic to Participate in Investor and Scientific Conferences in May
PR
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
AQ
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation
AQ
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
PR
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
CI
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
AQ
Transcript : Immunic, Inc. - Special Call
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
PR
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMUX Stock
  4. News Immunic, Inc.